INSM – Quick take on Insmed

 Insmed (NASDAQ: INSM) is expected to report top-line data from a Phase II trial of Arikace in non-tuberculosis mycobacteria (NTM) infection tomorrow morning. This is a double-blind placebo-controlled study that.

Corcept – Fourth time a charm?

Corcept Therapeutics (CORT) is currently awaiting topline Phase III data for Korlym(mifepristone) in psychotic depression in the second quarter. Currently, Corcept projects Korlym will do net revenue between $24-$28 million.

Quick Take on GERN Clinical Hold

Geron announced this morning the FDA had placed a clinical hold on its lead drug Imetelstat. While the agency cited only trials in ET, PV, and MM, the company also.

Upcoming events for Merck

Members of Chimera Research Group have successfully been trading Merck for the past few months, especially Joe Gantos(@GantosJ). Merck has been one of the strongest big pharmas over the past.

Upcoming events for Pfizer

Pfizer (PFE) isn’t traditionally on my watchlist as a name to follow, however, this may be an exception. Palbocicib is likely the most exciting pipeline product in development at Pfizer.

A look at Auspex Pharma

Lately, it seems like there is a new biotech IPO being filed every other day. Today, we want to take a look at a recent IPO, Auspex Pharmaceuticals (ASPX). Auspex.

High Risk, High Reward With GW Therapeutics (GWPH)

In just a year’s time, GW has morphed from a company focused on the marketing of an approved product to one dedicated to the development of an early stage orphan.

Update on Protalix

On Wednesday, Protalix (PLX) will present data from their phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. The presentation will be.

Arrowhead Research (ARWR)– Great Technology, But is the Company Over-Promising on ARC-520?

Two billion people globally have been infected with hepatitis B (HBV), and approximately 350 million are chronic carriers, including approximately 750,000 persons in the US. Among the chronically infected, 15%.

CYTK – Will tirasemtiv BENEFIT ALS patients?

  As Cytokinetics confirmed in its Q4 2013 conference call, it will report top-line data from the BENEFIT-ALS study in the second quarter of this year, precisely, at the American.

Prospects for Prana's PBT2

On the wildly speculative front, Prana Biotechnology (PRAN) is a developer of metal protein attenuating compounds(MPAC) for neurodegenerative disorders. Shares are up over 350% in the past year as the.

Upcoming Phase 3 trials

With a fresh start to 2014 and the biotech market still very strong, we wanted to examine some upcoming Phase 3 results that will be in focus in the first.

GERN- A Speculative Trade

To be clear, I’m not a big fan of Geron. However, upcoming events provide an interesting, although somewhat risky trading opportunity. The telomerase inhibitor imetelstat has demonstrated activity in the.

A look at Innate Pharma

Immuno-oncology was one of the hottest themes of 2013 and its been almost entirely a big pharma story. We saw Bristol-Myers Squibb, Merck and Roche reveal more data and future.

GenVec: hearing a comeback

On the verge of shutting down just a few months ago, Genvec (NASDAQ: GNVC) has recently had a comeback  that might last for a few more years if its partnered.

Quick Take On NBIX

I have not followed this story before today, but I’ll throw my hat into the ring anyways It looks like Phase 2b results turned out positive in this second study.

Analysis of TGR-1202, a PI3K Delta Inhibitor From TGTX

This is a quick take on the TGTX efficacy data presented at ASH this past weekend. TG Therapeutics reported PK data as well as results from the higher 800 mg.

SRPT – FDA Says No To Sarepta AA

On Tuesday morning, Sarepta informed investors that in what appeared to be a change from its previous stance, the FDA was not supportive of the company’s planned Accelerated Approval filing.

TSRO – A look at Tesaro

Following additional information released at ASCO 2013 and their recent quarterly updated, we wanted to take a moment to talk about Tesaro (TSRO). Since their IPO, Tesaro’s stock is up.

ASH 2013 Preview on ALL/CML/MDS/AML

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. The first series in our preview covered what to expect in.

ASH 2013 Preview on Myelofibrosis

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs.

ASH 2013 Preview on Lymphoid Malignancies

This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking.

ASH 2013 Preview on rare blood disorders

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. Orphan diseases has been a key element in the bull market.

ASH 2013 Preview on Multiple Myeloma

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs.

CLDX – A look at CDX-1127

Celldex Therapeutics (CLDX) has one of the most anticipated data releases amongst small biotech companies this fall. They are scheduled to present data from their Phase 1 dose-escalation trial of.

Ariad- Where Do They Go From Here

Following the FDA’s clinical hold, then discontinuation of the Phase III trial in front line CML for Ariad’s only marketed drug, Iclusig, the most pressing issue comes down to are.

Datasets in focus at IASLC this weekend

This weekend is the  15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th.

Biocryst up on hope(hype) for HAE prophylaxis

In a previous post, Jason Chew provided some background and analysis on Biocryst (BCRX) BCX4161, an oral drug candidate for the treatment of hereditary angioedema (HAE). Biocryst’s stock is up.

MDVN – Confusion over PREVAIL data explained in a single graph

On Tuesday, the market was rather confused on what to make of the PREVAIL news. To be clear, this wasn’t entirely the market’s fault: Medivation released a poorly worded press.

October 17- EOD

A mixed day in the market which was nice to see a day in which not all stocks were moving in the same direction. Obviously had some stock specific news.

PSDV ALIM – Analysis of Iluvien for DME

On Thursday, Alimera (ALIM) and Psivida (PSDV) are expected to hear from the FDA on the status of their new drug application(NDA) for Iluvien(fluocinolone acetonide intravitreal implant) to treat chronic.

Browsing 31 / 316 articles